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Netherlands from a societal perspective. Methods: Health care, patient and fam-
ily and other use of resources for five different categories of side-effects were 
measured by means of a questionnaire. Respondents were patients with epilepsy 
who experienced at least one side-effect due to antiepileptic treatment in the 
last 12 months. Results: Based on data from 203 chronic epilepsy patients, the 
overall societal costs of common side-effects in 2012 are estimated to be € 20,751 
(CI: 15,049-27,196) per patient per year in the base case analysis. These societal 
costs exist of: mean health care costs (€ 4,458), mean patient and family costs (i.e. 
informal care and out of pocket expenses) (€ 10,526) and mean other costs (i.e. pro-
ductivity and daily routine losses) (€ 5,761). Examining the different categories of 
side-effects separately, ranging from the most to the least expensive category, the 
cost estimates were as follows: other side-effects (€ 13,228), behavioral side-effects 
(€ 9,689), general health side-effects (€ 7,454), cognitive side-effects (€ 7,285) and 
cosmetic side-effects (€ 2,845) per patient per year. Subgroup analyses showed sig-
nificant differences in costs between patients using monotherapy and those using 
polytherapy when looking at cognitive and cosmetic side-effects. ConClusions: 
These estimates should be considered in the overall assessment of the economic 
impact of a pharmacotherapy.
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objeCtives: To assess resource utilization before and after the development of 
Alzheimer’s disease (AD), using the Quebec provincial drug reimbursement program 
database (RAMQ). Methods: This study included patients covered by the RAMQ 
who had at least one diagnosis of AD (ICD-9 code 3310) or have received at least 
one script for an AD medication (donepezil, rivastigmine, galantamine or meman-
tine) from January, 1985 to December, 2011. A control group of patients without AD 
was created on a 1:1 ratio and matched for age, gender and geographic location. 
The index date was defined as the date of the first AD diagnosis or the first script 
for AD medication whichever comes first. Health care resource costs were ana-
lyzed in terms of emergency room, outpatient clinic, intensive care unit and physi-
cian’s visits, hospitalizations and long-term care, plus AD medications and other 
medications costs. Annual health care costs were reported for the 5-years before 
and the 5-years after the index date. Results: Data were obtained for a random 
sample of 34,086 AD patients (mean age of 78.5 years [SD= 8.0], 65.2% females). 
Before the index date, health care costs were similar between AD patients and the 
control group, except for the year preceding AD. Indeed, cost per patient for this 
year increased from CDN$5,126 to CDN$8,839 for the AD group and from CDN$4,466 
to CDN$5,212 for the control group (72.4% vs. 16.7% increase respectively). For the 
5-year period after the index date, costs were significantly higher for AD patients 
with an average cost per patient per year of CDN$9,364 vs. CDN$5,864 for the control 
group (mean difference of CDN$3,500,p< 0.001). ConClusions: AD significantly 
increases health care resource costs, including medical resources and medications. 
Costs generated by AD patients cumulate over time leading to a major difference in 
long-term costs compared to non-AD patients.
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objeCtives: Parkinson Disease (PD) is the second commonest cause of neuro-
logical disability and affected approximately 5.2 million men and women world-
wide. Continuous subcutaneous apomorphine (CSAI) represents an alternative 
treatment option of advanced PD with motor fluctuation. The purpose of this 
analysis was to estimate the cost-effectiveness of CSAI compared with Levodopa/
carbidopa intestinal gel (LCIG), Deep-Brain-Stimulation (DBS) and Standard-of-care 
(SOC). Methods: We developed a multicounty Markov-Model to simulate the long-
term consequences, disease progression (Hoehn&Yahr-stages 3-5, percentage of 
waking-time in the OFF-state), complications and adverse-events. Complications 
are different for the alternatives (e.g. pump problems in case of LCIG, temporary/
permanent complications in case of DBS). We include moderate and severe adverse-
events and death. Monte-Carlo-simulation accounted for uncertainty. The model 
includes 25 health-states. Probabilities were derived from RCT and open-label stud-
ies; direct costs (2012) from published sources from the payer’s perspective (NHS and 
German health care systems). QALYs, life-years (LYs) and costs were projected over 
a life-time horizon and discounted according the national guidelines. Results: UK 
life-time costs associated with CSAI amounts to 70,258 £ and generates 2.85 QALYs 
and 6.28 LYs (106,530 € , 2.92 QALYs and 6.49 LYs for Germany). Costs associated 
with LCIG are 117,121 £, achieves 3.06 QALYs and 6.93 LYs (178,405 € , 3.18 QALYs and 
7.18 LYs for Germany). The incremental-cost per QALY gained (ICER) was 223,052 £ 
(281,089 € ). Costs for DBS are 88,361.61 £, associated with 2.75 QALYs and 6.38 LYs 
(121,988 € , 2.85 QALYs and 6.61 LYs for Germany). CSAI dominates DBS. SOC associ-
ated UK costs are 68,082.92 £; 2.62 QALYs and 5.76 LYs were reached (91,588 € , 2.7 
3QALYs and 6 LYs for Germany). ConClusions: CSAI is a cost-effective treatment 
alternative, reducing OFF-time and improving quality-of-life and is associated with 
a cost-advantage.
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were 178. The key cost driver for inpatients was daycare (hospitalization, medical 
and nursing care, therapies). ConClusions: The annual cost of treating patients 
with paraplegia in the private health care sector in Greece is high. This study is the 
first cost study in this disease area and additional studies should be undertaken in 
order to acquire a more complete picture of the cost of managing disease, in both 
the private and public health care sectors.
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objeCtives: PD-LID, a complication of L-Dopa treatment, is associated with inabil-
ity to perform daily living activities, reduction in quality of life and increase in 
health care costs. Limited data are currently available on the burden of this dis-
ease. LIDIA describes medical and non-medical resource utilization and economic 
impact of PD-LID patients from payer and society perspective according to LID 
severity: mild (mAIMS score< 8), moderate (mAIMS [8-12]) and severe (mAIMS> 12) 
patients. Methods: This observational, prospective, longitudinal, multicentre 6 
month-study was conducted by French neurologists specialized in Parkinson’s dis-
ease (PD). PD patients taking L-dopa for at least 3 years were included, with PD-LID 
present for more than 3 months and for more than 25% of the time. Results: 
Thirty-three neurologists included 186 patients (mean 68 years old, 52% women) 
with mean mAIMS score at 10. PD-LID patients were mainly followed by their neu-
rologists (96%) and general practitioner (GP) (84%) with more non-medical follow-up 
for severe patients. Almost 60% had at least one biological or radiological exami-
nation, only 31% required transport. All patients received L-Dopa (including 32% 
long-acting), and 69% dopaminergic agonists. Only 21% had at least one hospitali-
zation and over 40% needed home layout and mobility equipment. Most patients 
(70%) were assisted by a caregiver (24h/week), 43% required external assistance (6h/
week), 22% received an invalidity allowance. Total costs represent 35117€ , 33640€ and 
43739€ in respectively mild, moderate and severe patients (on average per patient/
year). Non-medical costs (transportations, paid external help, caregivers time, mobil-
ity equipment, home layout) are the major cost drivers (80%), including caregiver 
help (70%), followed by medical (consultations, treatments, hospitalizations)(15%) 
and indirect costs (allowances and work stoppages)(5%). ConClusions: The LIDIA 
study confirms that in this disabling disease, the economic burden is mainly sup-
ported by the patient family, with the payer part being 23%. Economic burden is 
greater in patients with severe dyskinesia.
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objeCtives: Herpes zoster (HZ) and its most common complication post-herpetic 
neuralgia (PHN: pain persisting months after the rash onset) are associated with 
substantial burden of disease. There is a sharp increase in incidence from the 
age of 50, impacting individuals, their relatives and society. The objective of our 
work was to conduct a critical review documenting the Humanistic, Economic and 
Societal Burden of HZ in Europe. Methods: Systematic searches were conducted in 
Medline, EMBASE, PSYCHINFO, EconLit, HEED and CRD databases, using a combina-
tion of search terms in title and abstracts. Articles, published from 2000 onwards, 
were selected for full review by two independent researchers in accordance with 
predefined eligibility criteria. Results: From a review of 1448 abstracts, 42 eligible 
articles, were identified which reported data concerning health care resource use 
(n= 26), direct costs (n= 21), indirect costs (n= 14), impact on health-related qual-
ity of life (HRQoL) (n= 21) and impact on caregivers (n= 3). Findings across studies 
highlight that levels of pain severity and the presence of PHN are associated with 
greater impairments in HRQoL and higher costs of management. At least 50% of 
employed patients missed work due to the disease. While the incidence of HZ and 
PHN increase with age, age was not a key driver of overall costs for HZ and PHN. 
Specifically, while direct costs (e.g. GP, specialists, medications, hospitalisations) 
tend to be higher for older patients, indirect costs (e.g. work time missed) are higher 
for younger patients. ConClusions: Available evidence highlights that HZ and 
PHN result in significant humanistic and economic burden for patients, health care 
systems and wider societies. There is a tendency to focus upon health care resource 
use and the direct costs of management which may result in an underestimation 
of the true burden of HZ and PHN, which is also expected to grow with the ageing 
European population.
PND24
siDe-effeCts of aNtiePilePtiC Drugs: tHe eCoNomiC burDeN
de Kinderen R.J.A.1, Evers S.M.1, Postulart D.2, Vader C.I.2, Majoie M.H.2, Aldenkamp A.P.2
1Maastricht University, Maastricht, The Netherlands, 2Epilepsy Center Kempenhaeghe, Heeze, The 
Netherlands
objeCtives: Epilepsy is a brain disorder which is characterized by recurrent 
unprovoked seizures. The outward effect of seizures can be as dramatic as a 
wild trashing movement or as mild as a brief loss of awareness. To reduce fre-
quency and severity of seizures, antiepileptic drugs are potentially an effective 
treatment for patients with epilepsy. However, side-effects are common. The 
negative consequences of side-effects can lead to treatment ranging from minor 
care to very expensive hospitalization. This cost analysis has been conducted 
to provide insight into the costs of side-effects due to antiepileptic drugs in The 
